Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service spinal cord & DRG stimulation cases in Minnesota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (170 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 12 | 497 | 49% |
| 2020 | 11 | 355 | 52% |
| 2021 | 13 | 393 | 56% |
| 2022 | 14 | 436 | 59% |
| 2023 | 12 | 381 | 62% |
| 2024 | 12 | 445 | 64% |
| 2025 from claims | – | 494 399–580 | 65% |
| 2026 forecast | – | 561 439–704 | 61% |
| 2027 forecast | – | 585 434–773 | 61% |
| 2028 forecast | – | 611 432–843 | 61% |
| 2029 forecast | – | 637 433–914 | 60% |
| 2030 forecast | – | 665 436–987 | 60% |
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 91% of the cases CMS names in Minnesota; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 13% hospital outpatient, 87% surgery center. The share outside the hospital has moved +17 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center |
|---|---|---|
| 2026 · ~560 | ~65 | ~500 |
| 2027 · ~590 | ~64 | ~520 |
| 2028 · ~610 | ~64 | ~550 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 89% (87% in 2025), hospital outpatient about 11% (13% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 22 | 900−1.9%/yr | −1.9%/yr | 0.7 | 32% | 1,040 in 2030+2.4%/yr |
| Indiana | 21 | 707−4.8%/yr | −4.8%/yr | 0.9 | 75% | 780 in 2030+1.7%/yr |
| Illinois | 20 | 692−5.2%/yr | −5.2%/yr | 0.5 | 47% | 820 in 2030+2.8%/yr |
| Missouri | 21 | 634−4.8%/yr | −4.8%/yr | 0.9 | 41% | 660 in 2030+0.5%/yr |
| Michigan | 13 | 535−8.6%/yr | −8.6%/yr | 0.6 | 51% | 480 in 2030−1.9%/yr |
| Kansas | 19 | 505−4.3%/yr | −4.3%/yr | 1.2 | 38% | 660 in 2030+4.7%/yr |
| Wisconsin | 10 | 363−4.6%/yr | −4.6%/yr | 0.6 | 50% | 420 in 2030+2.4%/yr |
| Nebraska | 5 | 200−5.3%/yr | −5.3%/yr | 0.7 | 65% | 270 in 2030+5.4%/yr |
| Iowa | 3 | 125−16%/yr | −16%/yr | 0.3 | 65% | 110 in 2030−1.9%/yr |
| South Dakota | 2 | 110−11%/yr | −11%/yr | 0.8 | 23% | 130 in 2030+3.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 88 | 4,824+0.9%/yr | +0.9%/yr | 10.11.2× | 73% | 6,880 in 2030+6.1%/yr |
| Peripheral nerve stimulation & intrathecal pumps | 10 | 570+1.3%/yr | +1.3%/yr | 1.11.0× | 65% | 1,150 in 2030+12%/yr |
Spinal cord & DRG stimulation in every state, and its device makers · Every procedure market in Minnesota · Every state · Compare with Ohio
Pacira Pharmaceuticals leads with 30% of company spending on these surgeons in 2025, −7 pts on 2024.
In 2025, 9 companies reported engagement with Minnesota’s surgeons worth $337K in consulting, speaking, meals and travel tied to these products, about $28K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 4 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.